Economics, Pharmaceutical
"Economics, Pharmaceutical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))
| Descriptor ID |
D017850
|
| MeSH Number(s) |
N03.219.390
|
| Concept/Terms |
Pharmacy Economics- Pharmacy Economics
- Economic, Pharmacy
- Economics, Pharmacy
- Pharmacy Economic
|
Below are MeSH descriptors whose meaning is more general than "Economics, Pharmaceutical".
Below are MeSH descriptors whose meaning is more specific than "Economics, Pharmaceutical".
This graph shows the total number of publications written about "Economics, Pharmaceutical" by people in this website by year, and whether "Economics, Pharmaceutical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Economics, Pharmaceutical" by people in Profiles.
-
Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009; 27(11):947-61.
-
Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008 Apr; 14(3 Suppl):S102-6.
-
Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. J Invasive Cardiol. 2003 Sep; 15(9):536-53.
-
Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology (Oxford). 2000 Dec; 39 Suppl 2:33-42; discussion 57-9.
-
Intravenous azithromycin. Ann Pharmacother. 1999 Feb; 33(2):218-28.
-
Re-examination of clinical aspects of pharmacoeconomic analysis. Am J Hosp Pharm. 1994 Dec 01; 51(23):2970-3.